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Most individuals identified as ultra-high-risk (UHR) for psychosis do not develop frank psychosis. They continue to exhibit subthreshold
symptoms, or go on to fully remit. Prior work has shown that the volume of CA1, a subfield of the hippocampus, is selectively reduced in
the early stages of schizophrenia. Here we aimed to determine whether patterns of volume change of CA1 are different in UHR individuals
who do or do not achieve symptomatic remission. Structural MRI scans were acquired at baseline and at 1–2 follow-up time points
(at 12-month intervals) from 147 UHR and healthy control subjects. An automated method (based on an ex vivo atlas of ultra-high-
resolution hippocampal tissue) was used to delineate the hippocampal subfields. Over time, a greater decline in bilateral CA1 subfield
volumes was found in the subgroup of UHR subjects whose subthreshold symptoms persisted (n= 40) and also those who developed
clinical psychosis (n= 12), compared with UHR subjects who remitted (n= 41) and healthy controls (n= 54). No baseline differences in
volumes of the overall hippocampus or its subfields were found among the groups. Moreover, the rate of volume decline of CA1, but not
of other hippocampal subfields, in the non-remitters was associated with increasing symptom severity over time. Thus, these findings
indicate that there is deterioration of CA1 volume in persistently symptomatic UHR individuals in proportion to symptomatic progression.
Neuropsychopharmacology (2017) 42, 1361–1370; doi:10.1038/npp.2017.5; published online 1 February 2017
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INTRODUCTION
Individuals at risk for psychosis are generally identified by
the presence of subthreshold symptoms. Many studies of this
population largely focus on examining characteristics of
at-risk subjects who subsequently develop full-blown psy-
chotic symptoms. Yet, the majority of the at-risk individuals
do not convert to frank psychosis (Simon et al, 2011). The
subthreshold symptoms observed at baseline typically either
persist or resolve over time. It has been argued that clinical
care for individuals with persistent subthreshold psychotic
symptoms is indicated, given the functional impairment seen
in this population (Carpenter, 2014). To stratify treatment
for at-risk individuals with varying outcomes (Kapur et al,
2012), attention needs to be directed towards understanding
the biological predictors of these potential outcomes, as it has
become increasingly clear that in psychiatric illnesses,
biological changes precede the appearance of symptoms in
a dimensional manner (Cuthbert and Insel, 2010).
Several lines of evidence suggest that abnormalities of the
hippocampus may represent candidate biological markers of
psychosis (Heckers and Konradi, 2010). Two recent in-
dependent large-scale consortium studies have separately
found the hippocampus to exhibit the most extensive volume
reductions among all of the subcortical brain regions
examined in schizophrenia (Okada et al, 2016; van Erp
et al, 2015). Also, several meta-analyses have consistently
found hippocampal volume reductions not just in chronic
schizophrenia but also within first-episode populations
(Adriano et al, 2012; Haijma et al, 2013). However, the
timing of the emergence of hippocampal abnormalities
during the course of the illness remains unclear.
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Findings from cross-sectional studies of hippocampal
volume in at-risk subjects, which have included familial
(first-degree relatives) and/or clinical (those with subsyn-
dromal symptoms) at-risk groups, have been mixed thus
far—with findings of volume reduction, or no changes
(Ganzola et al, 2014; Hurlemann et al, 2008; McDonald et al,
2006; O'Driscoll et al, 2001; Ongur et al, 2006; Seidman et al,
2002; Witthaus, 2010; Witthaus et al, 2009; Wood et al, 2005,
2010). Longitudinal studies of hippocampal volumes in at-
risk subjects could help to resolve the discrepancies among
prior findings by determining whether volume deficits of the
hippocampus are already present during the prodromal
phase of psychosis, and map the potential differences in the
trajectories of hippocampal volumes for subjects with
different outcomes.
Also, studies must now account for evidence that the
cytoarchitecturally distinct subfields of the hippocampus
(ie, CA1, CA2/3, CA4, dentate gyrus, and subiculum) are
differentially affected by the disease process associated with
psychosis (Talati et al, 2014), particularly early on in the
illness (Ho et al, 2016; Schobel et al, 2013). Metabolic
abnormalities selectively in the CA1 subfield of the
hippocampus have been found to precede the development
of psychosis and a subsequent change in the shape of a
hippocampal region likely corresponding to CA1 (Schobel
et al, 2013). Consistent with these findings, we recently
identified, using a validated automated method of segment-
ing the hippocampus (Iglesias et al, 2015), a selective volume
deficit in the CA1 subfield in early-course schizophrenia
patients (Ho et al, 2016). Therefore, in the current
investigation, we sought to extend this finding by determin-
ing whether CA1 volume deficits are present during the
prodrome and are predictive of persistence or worsening of
symptoms.
To test this hypothesis, we prospectively followed a group
of ultra-high-risk (UHR) individuals, who met the consensus
criteria for the UHR state (Yung et al, 2005), and healthy
control (HC) subjects, who reside in a region of the world
with one of the lowest rates of illicit substance use worldwide
(Lee et al, 2013) and thus are likely minimally affected by the
potentially confounding effects of substance use on hippo-
campal volume (Solowij et al, 2013; Thompson et al, 2004).
We collected MRI scans and clinical measures at the time of
recruitment (baseline), and at the 12- and 24-month follow-
up time points, or until the point of transition to clinical
psychosis. Based on prior work (Ho et al, 2016; Schobel et al,
2013), we predicted that we would observe a progressive
decline in volume of the CA1 subfield in the subgroup of
UHR subjects who exhibited persistent or worsening
symptoms (the ‘non-remitters’) but this decline would be
absent in the UHR subjects who remitted.
MATERIALS AND METHODS
Participants
We studied 93 UHR individuals and 54 HCs. These
participants were part of the Longitudinal Youth At-Risk
Study conducted from 2008 to the fall of 2015 in Singapore
(Lee et al, 2013; Wang et al, 2016). The UHR participants
met the criteria for the at-risk mental state defined by the
Comprehensive Assessment of At-Risk Mental States
(CAARMS) version 12/2006 (Yung et al, 2006), which
includes the positive subscale of the CAARMS and the
Social and Occupational Functioning Assessment Scale
(SOFAS) (Goldman et al, 1992; Yung et al, 2005); the youths
were of genetic risk for psychosis and/or showed subthres-
hold symptoms, and deterioration in functioning in the past
12 months. See Supplementary Methods S1 for details of the
recruitment and screening process.
Exclusion criteria for the UHR participants included (i)
past or current history of psychosis, or mental retardation,
(ii) any treatment with mood stabilizers or antipsychotic
medications, (iii) medical conditions that could account for
their prodromal psychotic symptoms, (iv) current substance
use, abuse, or dependence, and (v) current alcohol abuse or
dependence, assessed using the Structured Clinical Interview
for DSM-IV Axis I Disorders—Patient version (SCID-I/P)
(First, 2002b).
Exclusion criteria for the HC included (i) a history of
major psychiatric conditions, (ii) first-degree relatives with
any axis I disorder, and (iii) any history of substance or
alcohol abuse/dependence, assessed using the Structured
Clinical Interview for DSM-IV Axis I Disorders—Non-
Patient version (SCID-I/NP) (First MB, 2002a). In addition,
the HC did not meet the CAARMS criteria for UHR status.
General exclusion criteria for all of the subjects included
contraindications for MRI scans, and major medical condi-
tions. Ethics approval for this study was provided by the
Singapore National Healthcare Group’s Domain Specific
Review Board. Written informed consent was obtained from
all participants aged 21 years and above, or from a legally
acceptable representative for participants under 21 years of
age with their assent.
Clinical Measures
The CAARMS and SOFAS, as part of the CAARMS version
12/2006, were administered to the UHR subjects at 6-month
intervals, or until the point of transition to clinical psychosis.
The SCID-I/P was administered every 12 months to the UHR
subjects. The SCID-I/NP was administered to the HC
subjects during the baseline visit and at the end of follow-
up, which was 24 months later.
The UHR subjects were assigned to three different groups,
based on their combined CAARMS and SOFAS status at
their last MRI scan. UHR subjects were deemed to have
remitted if they no longer met the CAARMS/SOFAS criteria
for UHR status (UHR remitters, UHR-R). UHR subjects who
transitioned to psychosis during the course of study, and
UHR subjects who remained at risk because of persistent
prodromal symptoms were combined into one group to
afford greater power for subsequent analyses (UHR-non-
remitted, UHR-NR). Two of the UHR subjects with unstable
symptomatology, that is, who were symptom free for
12 months, and then experienced a second onset of
subsyndromal symptoms, were excluded from the primary
analysis.
MRI Acquisition and Image Processing
Parameters of the structural scans, which were performed at
baseline, 12 months, and 24 months, are detailed in
Supplementary Methods S2. The MRI scans were performed
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within 2 weeks after the clinical and neuropsychological
assessments were conducted.
Standard preprocessing of the structural images, followed by
longitudinal preprocessing steps that further reduced within-
subject variability, were performed using FreeSurfer version
5.3 (http://surfer.nmr.mgh.harvard.edu) (Fischl et al, 2002,
2004; Reuter et al, 2012). The segmentation of the hippo-
campus into its subfields was performed using a recently
validated segmentation algorithm that was based on an atlas
constructed from ultra-high-resolution ex vivo hippocampal
tissue (Iglesias et al, 2015). Details of these methods can be
found in Ho et al (2016). Visual quality control of the image
processing that included checking for excessive motion was
performed (Supplementary Methods S3). The proportion of
UHR subjects excluded because of motion was not different
from healthy subjects. Further, data set from an UHR-NR
subject was removed from the analysis because of poor
longitudinal image reconstruction. Hippocampal segmenta-
tion results were visually checked for each subject; there were
no instances of incomplete labeling of hippocampal sub-
regions or mislabeling of extrahippocampal regions in the
remaining 147 subjects.
Volumes of the seven subfields of the hippocampus
(Burwell and Agster, 2009): the GCL, CA4, CA2/3, CA1,
ML, the hippocampal tail, and the subiculum were extracted.
The volumes of the seven subfields for each hemisphere were
summed to obtain a measure of the volume of the global left
and global right hippocampus. To facilitate comparisons
with other studies, the volumes of the hippocampus (from
the standard output of the FreeSurfer automated labeling
of major subcortical structures) were also extracted for a
supplementary analysis.
Statistical Analyses
All analyses were performed using open-source R software
(version 3.2) (The R Core Team, 2015).
Participant characteristics. We examined three groups of
participants: HC, UHR-R, and UHR-NR. Baseline between-
group demographic, clinical, and cognitive differences were
tested using χ2 tests and analysis of variance (ANOVA).
Primary analyses. We tested whether there was a main
effect of group on baseline volumes, as well as an interaction
effect between group and time, by fitting a linear mixed-
effects model for each volume measure. Before model fitting,
Shapiro–Wilks test for normality and the Bartletts test of
homogeneity of variance were first performed to test for
normal distributions and equal variances of all the volume
measures of the hippocampus and subfields at each time
point among the groups.
In our model, the fixed-effects included group, time (in
months), interaction between group and time, ICV, baseline
age, and gender. Random effects included individual
intercept and individual slope of time. An autoregressive
structure was used to model the variance–covariance matrix,
which recognizes that proximal observations are more
correlated than distant observations. An ANOVA was
performed on the linear mixed-effects model to test whether
there was statistical evidence of group differences in intercept
(effect of group at baseline) and slope (interaction effect
between group and time). If so, this was followed by post hoc
pair-wise group comparisons using Wald tests to compute
asymptotic χ2 statistics, with p-values adjusted for between-
group multiple comparisons using the Holm–Bonferroni
method (Fox and Weisberg, 2011; Hothorn et al, 2008).
Secondary analyses. (1) We first tested whether the
presence of psychiatric comorbidity (ie, SCID-assessed
lifetime history of depressive spectrum disorders, anxiety
spectrum disorders, alcohol abuse/dependence, and/or sub-
stance abuse/dependence) influenced our primary hypoth-
eses by adjusting for comorbidity in the statistical model. (2)
We also tested whether treatment with antidepressants or
benzodiazepines at any time-point affected the findings by
adding these as time-varying predictors in the model. (3) We
then tested whether the inclusion of two subjects with
fluctuating symptoms over time impacted the primary
findings. (4) Last, we tested whether CA1 volume decline
was different in individuals who developed clinical psychosis,
by further subtyping the non-remitted UHR subjects into
those who remained symptomatic at a subthreshold level
(UHR-NR-non-psychosis or ‘non-converters’) and those
who transitioned to full psychosis (UHR-NR-psychosis or
‘converters’).
Post hoc correlations between symptoms and hippocampal
subfields found to exhibit group differences. We examined
the within-group relationship between rates of volume
change in the affected hippocampal subfields and symptoms.
First, we fitted linear mixed-effect models for symptom
measures, with CAARMS scores as dependent variables;
time, age, and gender as fixed-effect variables; and individual
intercept and slope of time as random-effect variables. The
slope estimates of the subjects’ measures of symptoms were
then regressed onto the slope estimates of the affected
hippocampal subfield volumes (extracted from the linear
mixed-effect models constructed for the above-mentioned
primary hypothesis).
RESULTS
Subject Cohort Characteristics at Baseline and Follow-
Up
At baseline, the three groups of subjects, the HC (n= 54),
UHR-R (n= 41), and UHR-NR (n= 52, including 12 whose
symptoms worsened to exceed subthreshold), were well
matched in terms of age, gender, ethnicity, handedness, and
ICV (which was used as an estimate of head size) (Table 1).
A further breakdown of the baseline clinical characteristics of
the UHR subpopulations, that is, a comparison of the UHR-
R and UHR-NR, found no group differences in CAARMS
scores, as well as the proportion of individuals with (1)
lifetime and/or current history of depressive or anxiety
disorder, (2) past history of alcohol abuse or dependence,
and/or (3) past history of substance abuse or dependence
(Supplementary Table S1).
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No Group Differences in Hippocampal Volumes at
Baseline
At baseline, no between-group differences in global measures
of bilateral hippocampal volumes were found; also, similar
results were found using the standard subcortical segmenta-
tion method (see Supplementary Table S2). However, a
significant group by time effect was found for the volume of
the right (but not the left) global hippocampus (F2, 148= 9.69,
p= 0.0001, Table 2A). Post hoc analyses found that UHR-NR,
compared with UHR-R and HC subjects, showed greater
decline in right hippocampal volume over time (HC and
UHR-NR groups: β= 3.7, χ2= 14.5, po0.0003; UHR-R and
UHR-NR group: β= 3.93, χ2= 17.8, po0.0001) (Figure 1a).
Progressive Volume Decline of the CA1 Subfield in Non-
Remitting UHR Subjects
We then tested our primary hypothesis that a volume decline
in CA1 would be observed over time in UHR-NR, compared
with UHR-R subjects. While no initial group differences
were found in the volume of CA1 in both the left and right
hemispheres, a significant group by time interaction effect
was observed (right: F2, 148= 9.115, p= 0.0002; left:
F2, 148= 3.077, p= 0.049; Table 2B). Post hoc analysis
(adjusted for multiple comparisons between groups) revealed
that the CA1 volume decline was more pronounced in the
UHR-NR compared with HC (right: β= 1.05, χ2= 7.33,
po0.013; left: β= 0.9, χ2= 5.74, p= 0.049) and UHR-R
subjects (right: β= 1.59, χ2= 18.15, po0.0001; left: β= 0.77,
χ2= 4.42, p= 0.07), but there was no such difference between
the UHR-NR and HC subjects (Figures 1b and c). These
findings remained unchanged after adjusting for comorbid-
ity (which had an effect on several other subfields but not
CA1; see Supplementary Table S3) and treatment with
benzodiazepine and antidepressant medication (Supple-
mentary Table S4A). Also, inclusion of two subjects with
fluctuating symptomatology (in a secondary analysis) did not
substantively alter the results (Supplementary Table S5).
No CA1 Volume Trajectory Differences Between Non-
Remitting Converters and Non-Converters
Secondary analyses of additional subgroups (UHR-R, UHR-
NR-non-psychosis, and UHR-NR-psychosis) and HC
Table 1 Baseline Sociodemographic, Imaging, and Clinical Characteristics of Three Groups Healthy Controls, UHR for Psychosis subjects
who Subsequently Remitted (UHR-R), and the Combined Group of UHR Subjects who Remained at Risk/Converted to Psychosis (UHR-NR)
Controls UHR-R UHR-NR χ2, F, or t
(d.f.)
p-Value
N (baseline scan) 54 41 52 (40 remained at risk, 12
converted)
— —
Gender 27M, 27F 27M, 14F 36M, 16F 4.64 (2) 0.10
Age (years) 21.22± 4.28, range 14–29 20.76± 3.33, range 14–29 21.96± 3.91 range 14–29 1.14 (2,90) 0.32
Ethnicity 28C, 14M, 10I, 2O 25C, 11M, 3I, 2O 40C, 8M, 4I 10.36 (6) 0.11
Handedness 47R, 2L, 5A 37R, 2L, 2A 41R, 6L, 5A 3.85 (4) 0.43
UHR subtype — 34 APS, 7 GRD 45 APS, 7 GRD 0.23 (1) 0.63
N with depressive and/or anxiety disorder
(%)
— 34 (82.9%) 39 (75%) 0.86 (1) 0.36
N with history of alcohol abuse/
dependence (%)
— 3 (7.3%) 4 (7.7%) 0.005 (1) 0.95
N with history of drug abuse/dependence
(%)
— 4 (9.8%) 1 (1.9%) 2.77 (1) 0.10
CAARMS composite scores — 22.56± 12.60 26.38± 16.74 1.22 (91) 0.23
Intracranial volume (mm3) 155 3021± 137362.2 1 594 989± 171744.8 1 572 357± 168665.9 0.79 (2, 90) 0.46
N (first/second follow-up) 31/20 38/9 25a/8b — —
N (antidepressants at baseline/first/second
follow-up)
— 13/8/3 30/5/5 — —
N (benzodiazepines at baseline/first/second
follow-up)
— 6/3/3 4/0/0 — —
N (antipsychotics at baseline/first/second
follow-up)
— — 0/0/2c
Abbreviations: A, ambidextrous; APS, attenuated psychotic syndrome; C, Chinese; CAARMS, Comprehensive Assessment of At-Risk Mental States; d.f., degrees of
freedom; F, females; I, Indian; L, left; M, males; M, Malay; MRI, magnetic resonance imaging; O, others; R, right; UHR, ultra-high-risk; V, vulnerability/genetic risk group.
Measures of continuous variables are indicated by their means± standard deviation. χ2, analysis of variance, or independent t-tests were used to examine possible group
differences in the variables.
aWe conducted the first follow-up MRI scan for 5 of the UHR subjects who had developed psychosis, but did not conduct the second follow-up scan for these five
subjects.
bAmong the subjects with second follow-up scans, one subject had converted to psychosis between the first and second follow-up, whereas one subject had converted
to psychosis 10 months after the second follow-up scan.
cAt the point of the second follow-up, two participants were newly diagnosed with clinical psychosis and were prescribed antipsychotics (risperidone and quetiapine).
The others were scanned before receiving medication.
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revealed significant group differences in the right CA1
volume trajectory (right: F3, 147= 6.9, p= 0.0002), while
group differences in the left CA1 were subtle (F3, 147= 2.36,
p= 0.074). Consistent with the findings of the primary
analysis, post hoc tests showed a steeper right CA1 volume
decline in the UHR-NR-non-psychosis group compared with
the UHR-R (β= 1.4, χ2= 11.9, p= 0.003), and also in the
UHR-NR-psychosis group compared with the HC group
(β= 1.93, χ2= 7.1, p= 0.03) and UHR-R group (β= 2.46,
χ2= 11.9, p= 0.003). The volume trajectories did not differ
between the UHR-NR-psychosis and UHR-NR-non-
psychosis groups.
Volume Trajectories of Other Hippocampal Subfields
With the exception of the right CA3 (F2, 148= 4.97,
p= 0.0082), the group by time effect was not observed in
the other subfields (Table 2C). UHR-NR subjects displayed a
steeper volume decline compared with HC (β=− 0.37,
χ2= 5.84, p= 0.03) and UHR-R subjects (β=− 0.46, χ2= 9.8,
p= 0.005) for the right CA3. However, when we accounted
for treatment with antidepressant and benzodiazepine
medications, there was no longer a significant group by
time effect for the right CA3 (Supplementary Table S4B).
Also, the secondary pair-wise comparisons among the
further subtyped UHR subjects and HC groups did not
reveal any significant group differences in CA3 volumes.
Rate of CA1 Volume Decline Correlates With Rate of
Worsening CAARMS Scores
We then examined whether there was a longitudinal
relationship between decline in volume of the affected
subfields, that is, right CA1, left CA1, and right CA3, and
Table 2 Summary Statistics of Changes in Volumes of The Hippocampus and its Subfields Over Time in HC Subjects, UHR-R Subjects, and
UHR-NR Subjects (Those who had Persistent Subthreshold Symptoms and Those who Subsequently Developed Clinical Psychosis)
ANOVA of group by
time
Post hoc statistics of group by time effect
UHR-R and HC UHR-NR and HC UHR-NR and UHR-R
(A) Global hippocampus
Left F2, 148= 0497, p= 0.61
Right F2, 148= 8.18, p= 0.0004
a β= 0.2, χ2= 0.09, p= 0.76,
CI=− 1.60, 0.48
β=− 2.94, χ2= 12.09, p= 0.0007,
CI=− 4.45, − 1.17
β=− 3.14, χ2= 15.06, p= 0.0002,
CI=− 1.60, 0.49
(B) CA1
Left CA1 F2, 148= 3.10, p= 0.048
a β=− 0.14, χ2= 0.23, p= 0.63,
CI=− 0.74, 0.45
β=− 0.9, χ2= 5.56, p= 0.05,
CI=− 0.16, − 0.15
β=− 0.76, χ2= 4.26, p= 0.07,
CI=− 1.46, − 0.02
Right CA1 F2, 148= 9.08, p= 0.0002
a β= 0.54, χ2= 2.93, p= 0.09,
CI=− 0.08, 1.16
β=− 1.05, χ2= 7.32, p= 0.007,
CI=− 1.8, − 0.28
β=− 1.6, χ2= 18.15, po0.0001,
CI=− 2.33, − 0.85
(C) Other hippocampal subfields
Left GCL F2, 148= 0.72, p= 0.49
Right GCL F2, 148= 1.40, p= 0.25
Left CA4 F2, 148= 0.62, p= 0.54
Right CA4 F2, 148= 1.24, p= 0.30
Left CA3 F2, 148= 0.83, p= 0.43
Right CA3 F2, 148= 4.97, p= 0.008
a β= 0.09, χ2= 0.56, p= 0.46,
CI=− 0.15, 0.33
β=− 0.37, χ2= 5.84, p= 0.031,
CI=− 0.68, − 0.068
β=− 0.46, χ2= 9.78, p= 0.005,
CI=− 0.76, − 0.17
Left molecular
layer
F2, 148= 0.76, p= 0.47
Right molecular
layer
F2, 148= 2.65, p= 0.07
Left subiculum F2, 148= 0.91, p= 0.40
Right subiculum F2, 148= 0.60, p= 0.55
Left tail F2, 148= 0.55, p= 0.58
Right tail F2, 148= 1.38, p= 0.26
Abbreviations: ANOVA, analysis of variance; CI, confidence interval; HC, healthy control; UHR, ultra-high-risk; UHR-NR, non-remitted UHR; UHR-R, remitted UHR.
A linear mixed-effects model was used to test whether there were group differences in volume measures over time. As there were three groups, an ANOVA was first
performed to test whether there was statistical evidence of a group by time effect on the following measures: (A) the global hippocampus, that is, the sum of the seven
subfields of the hippocampus in the left and right hemisphere of the brain, (B) a priori CA1 hippocampal subfields; and (C) the other subfields of the hippocampus.
aSignificance at a threshold of po0.05. Post hoc pair-wise group comparisons were then performed using Wald tests (based on sampling covariance matrix of the
parameter estimates) to compute an asymptotic χ2, with p-values were adjusted for multiple comparisons between the groups using the Holm–Bonferroni method. The
βs indicate the differences in slopes between the two groups. For example, in the case of right CA1, the slope of UHR-NR relative to HC is − 1.05 per month. The βs
can be considered as unstandardized effect sizes. The 95% CIs are also shown; a CI covering the value of zero means the null hypothesis cannot be rejected.
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change in symptom scores in the UHR-NR group. We found
an association between the rates of volume decline of CA1
and rates of increasing severity in CAARMS composite
scores (right CA1: r=− 0.30, p= 0.03; Figure 2a; left CA1:
r=− 0.26, p= 0.05; Figure 2b). This relationship was not
found for the right CA3 volumes. Also see Supplementary
Figure S1.
DISCUSSION
Summary of Main Findings
At baseline, no volume deficits of the hippocampus or of any
of its subfields were observed in a cohort of UHR young
adults. Over time, however, progressive decline of the
volume of the CA1 subfield was found in UHR subjects
who remained persistently symptomatic or developed full-
blown psychosis. Moreover, the decline in CA1 volume in
this non-remitting group was associated with increasing
Figure 1 CA1 volume declines over time in ultra-high-risk (UHR)
subjects showing persistent or worsening symptoms. Compared with
healthy controls (HCs) and UHR subjects who remitted (UHR-R), the UHR
‘non-remitters’, whose symptoms persisted or worsened over time (UHR-
NR), showed steeper progressive decline in volume in measures of the (a)
right hippocampus, that is, sum of hippocampal subfields in the right
hemisphere, (b) right CA1, and (c) left CA1. The bars at the bottom of the x
axis represent the number of observations over time.
Figure 2 CA1 volume decline is associated with worsening of symptoms
over time. In the ultra-high-risk non-remitters (UHR-NR), an inverse
correlation was found between the rate of change in Comprehensive
Assessment of At-Risk Mental States (CAARMS) scores and the (a) rate of
change in right CA1 volume and (b) rate of change in left CA1 volume. Black
circles indicate UHR-NR subjects who have persistent but subthreshold
symptoms (UHR-NR-non-psychosis); open circles indicate UHR subjects
who developed clinical psychosis (UHR-NR-psychosis). Secondary analyses
revealed no differences in these CA1 volume–symptom relationships
between the UHR-NR-non-psychosis and UHR-R-psychosis groups.
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symptom severity. In contrast, CA1 volume remained
unchanged in UHR individuals who remitted.
No Initial Hippocampus Volume Deficit in At-Risk
Individuals
The absence of baseline global hippocampal volume deficits
in UHR subjects observed here agrees with findings of some
prior studies (Buehlmann et al, 2010; Cannon et al, 2015;
Klauser et al, 2015; Schobel et al, 2013; Velakoulis et al, 2006)
but not others (Dean et al, 2015; Francis et al, 2013;
O'Driscoll et al, 2001; Seidman et al, 2002, 2014; Wood et al,
2010). The inconsistency of results of prior studies may be
related to variability across studies in the phases at which the
UHR subjects were studied, for example, some of the studies
may have captured subjects during the late prodrome (when
hippocampal changes may have begun or at least become
detectable at a macroscopic level), while others may have
assessed subjects in early prodromal stages (before measur-
able changes in hippocampal volumes have occurred)
(Addington and Heinssen, 2012; Fusar-Poli et al, 2014).
The discrepancies in this literature may also be related to
methodologic differences across studies and/or heterogeneity
within and across cohorts, that is, variability in MRI
acquisition parameters (Bois et al, 2014; O'Driscoll et al,
2001; Seidman et al, 2002) and hippocampal analyses methods
used (Bois et al, 2014; Dean et al, 2015; Fusar-Poli et al, 2011),
as well as the potentially confounding effects of comorbid
mood, anxiety, and substance abuse disorders that have been
linked to alterations in hippocampal structure and function
(Cha et al, 2016; Smith et al, 2015; Whittle et al, 2014). Of
note, the UHR subjects in the present study cohort were never
treated with antipsychotic and mood-stabilizing medications,
and predominantly lacked histories of substance abuse.
Emergence of CA1 Volume Decline in At-Risk
Individuals Differentiates Non-Remitters From
Remitters
Gradual volume decline in bilateral CA1 and right CA3—but
not in other hippocampal subfields—was found in subjects
who remained persistently symptomatic at a subthreshold
level, or whose symptoms worsened to the point of meeting
criteria for an episode of clinical psychosis. The trajectory of
CA1 volume changes observed here in non-remitting UHR
subjects is similar to the pattern of hypermetabolism, which
preceded shape abnormalities, of CA1 that was previously
found in clinical high-risk subjects who transitioned to
psychosis (Schobel et al, 2013). In a recent study, we reported
a selective CA1 volume deficit in subjects in the early stages
of schizophrenia (Ho et al, 2016). The current observation of a
similar pattern of findings in UHR subjects further indicates
that changes in the CA1 subfield of the hippocampus occur
early on in the illness process and are not attributable to
secondary effects of having the illness, such as treatment or
chronicity. In addition, the finding of an association between
progressive CA1 volume decline in the UHR-NR subjects and
increasing symptom severity replicates a similar association
observed in patients with schizophrenia (Ho et al, 2016).
Taken together, these findings provide converging evidence
that CA1 atrophy over time, regardless of illness stage, is
closely linked to clinical deterioration.
As the transition to frank psychosis is clinically defined, it is
unclear whether criteria for a psychosis diagnosis can be
precisely demarcated by any biomarker threshold (Yung et al,
2010). Recently, converging clinical, cognitive, biological, and
genetic evidence across psychotic spectrum disorders, and at
both early and chronic stages, has supported a dimensional
model of psychosis (Craddock et al, 2009; Hill et al, 2013;
Kuswanto et al, 2016; O'Donovan et al, 2009; Reininghaus
et al, 2013; Tamminga et al, 2013). Consistent with this model,
the findings of minimal CA1 volume trajectory differences
between the non-remitters who remained persistently symp-
tomatic at a subthreshold level and those who progressed to
full-blown psychosis suggest that the CA1 volume changes
may be most closely linked, in a dimensional manner, to
the emergence of psychotic symptoms, rather than to the
diagnosis of schizophrenia per se.
Possible Underlying Cellular Mechanisms
The progressive reduction of CA1 volume in individuals with
persistent subthreshold symptoms could be related to
changes in neuronal, glial, synaptic or vascular cytoarchi-
tecture, or density over time (Ho et al, 2013). Post-mortem
studies attempting to identify cytoarchitectural changes in
the hippocampus in schizophrenia have generally found no
reductions in the number of pyramidal neurons (Heckers
et al, 1991; Konradi et al, 2011; Walker et al, 2002) but some
evidence for decreased neuronal size and dendritic density
throughout the hippocampus (Arnold et al, 1995; Benes et al,
1991, 2001; Rosoklija et al, 2000; Zaidel et al, 1997). Among
the hippocampal subfields, CA1 has the largest number of γ-
aminobutyric acid interneurons, which are decreased in
density in patients with schizophrenia (Konradi et al, 2011).
Based on this finding and related work, it has been proposed
that the balance between excitation and inhibition is
disrupted in CA1, as a result of either blockage of the N-
methyl-D-aspartate receptors on interneurons or a reduction
in the number of interneurons, leading to disinhibition of the
CA1 pyramidal cells (Heckers and Konradi, 2015; Lisman
et al, 2010). Extending this hypothesis, we suggest that this
excitatory–inhibitory imbalance leads to alterations in
synaptic architecture and density in CA1, and an overall
thinning of the CA1 apical neuropil.
Limitations and Future Directions
These findings should be viewed in light of several
limitations of the study. First, the sample size of the
converters is modest. The rates of conversion in the present
sample cohort (14%) are lower than the initial UHR cohorts
(~30–40%) (Cannon et al, 2008; Yung et al, 2003), although
they are similar to recent at-risk cohorts across multiple
worldwide sites (Cannon et al, 2016; Carrion et al, 2016;
Ruhrmann et al, 2010); indeed, rates of conversion have been
steadily declining over the past decade to ~ 7–15% (Fusar-
Poli et al, 2015; Hartmann et al, 2016).
Second, the present findings of progressive CA1 volume
decline in the converters was significant only in the right
hemisphere; this appears inconsistent with prior work in
prodromal subjects, which detected metabolic and shape
changes primarily in the left CA1 (Schobel et al, 2013).
However, it is notable that both the prior and current study
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observed similar trends in the contralateral hemisphere. In
light of this and the modest sample sizes of these studies,
differences in image acquisition and analysis methods, as
well as the lack of evidence for any strong laterality of
hippocampal abnormalities in schizophrenia (Okada et al,
2016), we suggest that the changes in CA1 volume over time
associated with psychotic symptoms are not limited to one
hemisphere.
Third, the internal boundaries of the hippocampal
subfields are not visible at 1 mm resolution, thus the
automated segmentation method relies heavily on prior
knowledge (ie, the probabilistic ex vivo atlas). While
segmentations on 1 mm data cannot delineate the subfields
as accurately as higher resolution scans, it has been shown,
on several large publicly available data sets of different age
groups and disorders, that the segmentations on 1mm scans
are highly reliable (Whelan et al, 2016), even across different
MRI scanner platforms and field strengths (Whelan et al,
2016). Also, on large data sets with the same resolution as
our data, it has been demonstrated that the segmentations
based on local changes within the hippocampal subfield(s)
can discriminate between diseased and healthy states with
higher accuracy than the whole hippocampus (Iglesias et al,
2015).
Future larger-scale, prospective studies of UHR subjects
could assess the value of including a CA1 volume measure in
a multidomain index, which may include proinflammatory
cytokines in the plasma (Cannon et al, 2015), negative
symptoms (Piskulic et al, 2012), cognitive abilities (Lin et al,
2013), and white matter markers (Bloemen et al, 2010),
designed to predict risk and transition to full psychosis.
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